{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:17:00Z","timestamp":1774585020443,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.rdc.2016.09.005","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T00:02:46Z","timestamp":1477094566000},"page":"27-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Opportunistic Infections in Biological Therapy, Risk and Prevention"],"prefix":"10.1016","volume":"43","author":[{"given":"Paul A.","family":"Bryant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Baddley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.rdc.2016.09.005_bib1","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1073\/pnas.95.24.14447","article-title":"Perturbation of the T\u00a0cell repertoire in rheumatoid arthritis","volume":"95","author":"Wagner","year":"1998","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.005_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molmed.2004.01.002","article-title":"T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection","volume":"10","author":"Vallejo","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.005_bib4","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.rdc.2016.09.005_bib5","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.005_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.005_bib7","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib9","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the Safety Assessment of Biologic ThERapy (SABER) Study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00535-012-0686-9","article-title":"A\u00a0prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"48","author":"Naganuma","year":"2013","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.rdc.2016.09.005_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.04.001","article-title":"Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-alpha drugs","volume":"42","author":"Nguyen-Khoa","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10096-008-0628-x","article-title":"Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention","volume":"28","author":"Garcia-Vidal","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept, and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","article-title":"Update on the safety profile of certolizumab pegol in rheumatoid arthritis: in integrated analysis from clinical trials","volume":"74","author":"Bykerk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib15","first-page":"1","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"0","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib16","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib17","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Disease Society of America. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf. Accessed April 10, 2016."},{"issue":"12","key":"10.1016\/j.rdc.2016.09.005_bib18","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib19","unstructured":"World Health Organization (WHO) Global Tuberculosis Report 2015. Available at: www.who.int\/tb\/publications\/global_report\/en. Accessed April 10, 2016."},{"key":"10.1016\/j.rdc.2016.09.005_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib21","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib23","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.110373","article-title":"Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers","volume":"38","author":"Kim","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00408-013-9481-5","article-title":"Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea","volume":"191","author":"Lee","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.rdc.2016.09.005_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib26","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/j.crohns.2013.03.004","article-title":"Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: an analysis of 25 patients matched with a control population","volume":"7","author":"Abreu","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.rdc.2016.09.005_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3349\/ymj.2014.55.2.442","article-title":"Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-alpha therapy","volume":"55","author":"Yoo","year":"2014","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.rdc.2016.09.005_bib28","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2013-204960","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","volume":"74","author":"Arkema","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib30","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib31","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib33","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib34","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib35","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib36","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1086\/648443","article-title":"Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology","volume":"49","author":"Cassidy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib37","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features; an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00408-010-9241-8","article-title":"Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics","volume":"188","author":"Marras","year":"2010","journal-title":"Lung"},{"key":"10.1016\/j.rdc.2016.09.005_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice. Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib41","unstructured":"Centers for Disease Control and Prevention. Shingles (Herpes Zoster). Available at: http:\/\/www.cdc.gov\/shingles\/about\/overview.html. Accessed April 10, 2016."},{"key":"10.1016\/j.rdc.2016.09.005_bib42","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","article-title":"The incidence of herpes zoster in a United States administrative database","volume":"20","author":"Insinga","year":"2005","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib43","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2016.09.005_bib45","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib46","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2016.09.005_bib47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2016.09.005_bib49","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3 Pt 1","key":"10.1016\/j.rdc.2016.09.005_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/jid.2011.383","article-title":"Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry","volume":"132","author":"Serac","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108,604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.rdc.2016.09.005_bib52","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of Herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2016.09.005_bib53","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/651078","article-title":"Increasing incidence of herpes zoster among veterans","volume":"50","author":"Rimland","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib54","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A\u00a0population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.rdc.2016.09.005_bib55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib56","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A\u00a0vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"RR-5","key":"10.1016\/j.rdc.2016.09.005_bib57","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.005_bib58","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in auto-immune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib59","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJM198112103052402","article-title":"An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction","volume":"305","author":"Masur","year":"1981","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/thx.46.3.205","article-title":"Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis","volume":"46","author":"Wollner","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.rdc.2016.09.005_bib61","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"3 Pt 1","key":"10.1016\/j.rdc.2016.09.005_bib62","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2016.09.005_bib63","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/41.8.951","article-title":"Pneumocystis carinii pneumonia following a second infusion of infliximab","volume":"41","author":"Tai","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2016.09.005_bib64","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.rdc.2016.09.005_bib65","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/art.27735","article-title":"Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996\u20132007","volume":"62","author":"Louie","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib66","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib69","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib70","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long term Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.005_bib71","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rdc.2016.09.005_bib72","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12119","article-title":"Pneumocystis pneumonia in solid organ transplantation","volume":"13","author":"Martin","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rdc.2016.09.005_bib73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodoras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2016.09.005_bib74","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor \u03b1 antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib75","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3201\/eid1709.101987","article-title":"Geographic distribution of endemic fungal infections among older persons, United States","volume":"17","author":"Baddley","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib76","unstructured":"U.S. Food and Drug Administration 2008. Manufacturers of TNF-blocker drugs must highlight risk of fungal infections. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2008\/ucm116942.htm. Accessed April 11, 2016."},{"key":"10.1016\/j.rdc.2016.09.005_bib77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2334-11-145","article-title":"Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009","volume":"11","author":"Olson","year":"2011","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ299","article-title":"Histoplasmosis complicating tumor necrosis factor-\u03b1 blocker therapy: a retrospective analysis of 98 cases","volume":"61","author":"Vergidis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rdc.2016.09.005_bib80","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.005_bib81","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/acr.21784","article-title":"Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs","volume":"64","author":"Taroumian","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X16300564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X16300564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:14:48Z","timestamp":1760181288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X16300564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0889857X16300564"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2016.09.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunistic Infections in Biological Therapy, Risk and Prevention","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2016.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}